G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

- Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically Relevant Endpoints Across Multiple Hematopoietic Lineages, Including Hematologic Adverse Events, Laboratory Values, and Use of Supportive Care Interventions -

G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will participate in the 20th Annual Needham Virtual Healthcare Conference. The fireside chat will take place on April 14th at 12:45 PM EDT. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual COSELA Kickoff Analyst and Investor Summit on Friday, April 9, 2021 from 9:00 a.m. to 11:00 a.m. EDT.

G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021

COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors

G1 Therapeutics' COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology

RESEARCH TRIANGLE PARK, N.C., March 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two investor conferences in March.

G1 Therapeutics to Participate in Two Investor Conferences in March

G1 Therapeutics' first in class drug, Myelosuppression drug, Cosela has blockbuster potential.

G1 Therapeutics - Brighter Days Ahead

- Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutions - - Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutions -

G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

G1 Therapeutics' (GTHX) CEO Jack Bailey on Q4 2020 Results - Earnings Call Transcript

Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 28.72% year over year to ($0.67), which beat the estimate of ($0.87).

Recap: G1 Therapeutics Q4 Earnings

- G1's COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March -

G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the fourth quarter and full year of 2020 on Wednesday, February 24, 2021 at 4:30 p.m. ET.

G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021

G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone marrow) in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small-cell lung cancer. COSELA is administered intravenously as a 30-minute infusion within four hours before the start of chemotherapy.

G1 Therapeutics' Trilaciclib Wins FDA Nod For Mitigating Chemo Effects In Lung Cancer Patients

- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy -

FDA Approves G1 Therapeutics' COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will participate in the Guggenheim Healthcare Talks: 2021 Oncology Day conference. The fireside chat will take place on February 11, 2021 at 2:00 PM ET. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors' and officers' possible violations of state laws. If you purchased G1 Therapeutics stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 530, New York, NY 1

Glancy Prongay & Murray LLP Announces Investigation of G1 Therapeutics, Inc.

G1 Therapeutics has a PDUFA date coming up on February 15, 2021 for its first therapy, trilaciclib in SCLC. G1's stock has moved hugely upward over the last few months as investors begin to anticipate the likely approval.

G1 Therapeutics Likely Still Has Long-Term Upside Ahead Of The Trilaciclib PDUFA Date

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will present a company update at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 p.m. ET.

G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

- Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) -

G1 Therapeutics Announces Appointment of William C. Roberts as Vice President, Investor Relations & Corporate Communications

Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader (SERD) rintodestrant for ER+, HER2- breast cancer Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader (SERD) rintodestrant for ER+, HER2- breast cancer

G1 Therapeutics Presents Final Phase 2 Clinical Data on Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival at 2020 San Antonio Breast Cancer Symposium

GTHX stock is depressed but I don't see any reason. PDUFA of Feb. 15, 2021, is a major catalyst.

G1 Therapeutics: Depressed Price Before Catalyst, No Apparent Reason

RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey and Chief Medical Officer and Senior Vice President, R&D Raj Malik, M.D. will present a company update at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020 at 1:00 p.m. ET.

G1 Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020

Avis Budget Group

Biglari Hlds

GreenSky

Keros Therapeutics

Organogenesis Holdings

Reynolds Consumer Products

Waitr Holdings Inc

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was before and after the elections and as the pandemic worsens.

Last Week's Notable Insider Buys: Avis, Biglari And More

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its randomized Phase 2 trial of trilaciclib in metastatic triple-negative breast cancer (mTNBC) were consistent with preliminary findings announced last year, and showed that trilaciclib significantly improved median OS for patients treated with trilaciclib in combination with a chemotherapy regimen of gemcitabine/carboplatin. These data will be presented in a Spotlight Poster Session at the 2020 San Antonio Breast Cancer Symposium (SABCS) on Wednesday, December 9. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)

RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will present a company update at the Stifel 2020 Virtual Healthcare conference on November 18, 2020 at 11:20 a.m. ET.

G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2020 Results - Earnings Call Transcript

News for G1 Therapeutics Stock (GTHX)